Standout Papers

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from th... 2022 2026 2023 2024203
  1. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial (2022)
    April W. Armstrong, Melinda Gooderham et al. Journal of the American Academy of Dermatology

Immediate Impact

1 by Nobel laureates 1 from Science/Nature 57 standout
Sub-graph 1 of 25

Citing Papers

Atopic dermatitis
2025 Standout
Deuterium in drug discovery: progress, opportunities and challenges
2023 Standout
1 intermediate paper

Works of Steve Schoenfeld being referenced

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
2022 Standout

Author Peers

Author Last Decade Papers Cites
Steve Schoenfeld 65 82 73 160 15 346
Keystone Ec 41 48 19 88 15 358
Soyi Liu-Léage 73 115 39 76 21 386
Y. Zhang 30 50 12 163 22 392
Katalin Horvatovich 72 19 121 98 15 362
Andrea Ottria 26 30 14 151 15 371
J. G. Simpson 20 58 13 66 18 359
Laurindo Ferreira da Rocha 10 62 24 167 17 367
Ming-Huei Cheng 64 44 23 29 20 356
Francesca Ramazzotto 89 61 103 86 15 347
Clinton C. Bertram 24 23 21 112 13 355

All Works

Loading papers...

Rankless by CCL
2026